Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.

Abstract: A mechatronic device includes two arms extending from a base in a first direction and shaped to be handheld by an operator, the two arms having free ends forming a gripper and arranged to move closer together by rotation from a rest position to an active position, a motor housed in the base, an actuator mounted between the arms, and a means for controlling said actuator, the actuator connected to the motor so as to be driven in movement in translation in the first direction. The actuator also has a first contact surface that forms a cam with a respective second contact surface on each arm, the first contact surface remaining engaged with the second contact surface. The control means controls the movement in translation of the actuator to produce a movement in rotation of the arms that applies a chosen force of the gripper in its active position.

Abstract: The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.

Abstract: A laser source for emitting radiation in a given emission spectral band, centered on a given emission angular frequency, the central emission angular frequency is provided. The laser source comprises a laser cavity comprising a gain section having a known frequency dependent Group Delay Dispersion, and a GTI mirror arranged at one end of the gain section, having a known frequency dependent Group Delay Dispersion. The gain section and the GTI mirror are formed into a same laser medium, the laser medium having a known frequency dependent Group Delay Dispersion, and the gain section and the GTI mirror are separated by a gap of predetermined width filled with a dielectric medium thus forming a two parts laser cavity. Further, the GTI GDD at least partly compensates the sum of the Gain GDD and the material GDD in the emission spectral band.

Abstract: A multi-spectral photodetector is provided, comprising: a plurality of N photodetectors where N is an integer such that N?2, each photodetector comprising an anode and a cathode separated from one another by a region of interest, all produced in a semiconductor material; at least one electrical contact for all of the N anodes; and an electrical contact associated with each of the N cathodes; said photodetectors being stacked on top of one another such that the anodes and the cathodes and finally the regions of interest of two consecutive photodetectors in the stack are arranged face to face, this stack making it possible to define a face, termed the active face of the multi-spectral photodetector, common to all the photodetectors of the stack, defined by the face of the first region of interest of the first photodetector of the stack via which photons are intended to enter the stack.

Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

Abstract: Disclosed is a piezoelectric transducer of the type including a stack of a contact piece, a piezoelectric pellet and a support of very great stiffness. Specifically, the contact piece forms tips, the respective apex of which constitutes contact points that are spatially isolated from one another. Also disclosed is a process for the manufacture of such a contact piece as well as a resonant ultrasound spectroscopy device including one or more of such piezoelectric transducers.

Abstract: Provided herein is a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method including the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation-maximization technique on data relative to biomarkers.

Abstract: The present invention relates to a method to analyse the ability of a substance (3) to cross a bilayer membrane comprising the following steps: (i) providing in a hydrophobic medium (1) a first droplet D1 of an aqueous solution AS1, wherein the droplet D1 is surrounded by a monolayer of amphiphilic molecules (2), (ii) providing in the said hydrophobic medium (1) a second droplet D2 of an aqueous solution AS2 containing the substance (3) to be analysed, wherein the droplet D2 is surrounded by a monolayer of amphiphilic molecules (2), (iii) putting the first droplet D1 and the second droplet D2 into contact so as to form a bilayer of amphiphilic molecules (2) in the contact area and to have a contact angle 2? between the two droplets D1 and D2 comprised between 10° and 180°, (iv) adding to the hydrophobic medium (1) a solvent capable of separating the droplets D1 and D2 put into contact, (v) collecting the droplet D1, and (vi) analysing the content of the droplet D1 in order to determine the presence or not of

Abstract: A medical system comprising: a robotic arm, a control unit configured to issue a control signal, a medical device intended to penetrate an anatomical structure, the medical device being configured to emit a warning signal which varies as a function of a variable electrical characteristic of the anatomical structure, said medical device comprising a body with first and second electrodes, an electric generator suitable for applying at least one measurement electric current between the first and second electrodes, and a processing device suitable for determining a measurement parameter related to the electrical characteristic, based on said at least one measurement electric current, and for emitting the warning signal corresponding to the measurement parameter, wherein the control unit is configured to issue the control signal as a function of the warning signal.

Abstract: Compounds, compositions and their use in the treatment or prevention of symptoms of Lowe Syndrome and Dent disease 2 are described, for instance, the use of such compounds in the treatment of Lowe Syndrome and Dent disease 2, or in the treatment or prevention of at least one symptom associated therewith.

Abstract: The disclosure pertains to the field of molecular means capable of binding to, and preferably of chelating, cGMP, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. The polypeptides of the disclosure comprise a chimeric construction derived from the N terminus part of PKG-I? and PKG-I?, and the two cGMP binding sites of the wild type PKG.

Abstract: A method for establishing an Internet access by using a WLAN protocol from a mobile client station, via an access point to be chosen from a set of identified access points, includes: providing a general database of the identified access points with connection information; requesting Internet access using the protocol, successively moving through browsing through, selecting, associating, authenticating and configuring; establishing the Internet access of the mobile client station via the selected access point. Before and independently of the requesting the Internet access, connection information of at least a portion of the access points of the general database is downloaded into an onboard database of the mobile client station. The browsing through and selecting are carried out based on the downloaded connection information, without soliciting the general database and the identified access points.

Abstract: Disclosed is a lithography process on a sample with at least one emitter, the process including: putting at least one layer of resist above the sample; exciting one selected emitter with light through the at least one layer of resist; detecting light emitted by the excited selected emitter and determining a position of the selected emitter; and curing with a light beam a part of the at least one layer of resist above the position of the selected emitter, the light beam being a shaped light beam having a cross-section, this cross-section having a central part, an intermediate part surrounding the central part and a border part surrounding the intermediate part, the intensity of the shaped light beam on the at least one layer of resist reaching a maximum at the intermediate part.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: A device for cell culture, in particular of neuronal cells, including: a substrate defining a first microfluidic chamber to be seeded with a first cell culture, and at least a second microfluidic chamber, a fluidic interconnection system connecting the first and second chambers and enabling cellular extensions, in particular axons, to extend from one chamber to the other, wherein the interconnection system of the device is made so as to promote the progression of at least one first type of cellular extension, the first and second types of extension being different either due to the microfluidic chamber from which they originate, or due to the type of cell of which they constitute an extension.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.

Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.

Abstract: This execution method comprises the supplying of the machine code, this machine code being formed by a succession of base blocks, each base block being associated with a signature and comprising instructions to be protected, each instruction to be protected being immediately preceded or followed by an instruction for constructing the value of the signature associated with this base block, wherein: each construction instruction is coded on strictly less than N bits, and each word of the machine code which comprises at least one portion of one of said instructions to be protected also comprises one of said construction instructions so that it is not possible to load an instruction to be protected into an execution file, without at the same time loading a construction instruction which modifies the value of the signature associated with this base block when it is executed.